Caisson Transcatheter Mitral Valve Replacement (TMVR)

Not Applicable

Active, not recruiting

• Conditions: Valve Disease, Heart; Valve Heart Disease; Mitral Regurgitation; Mitral Valve Disease; Mitral Valve Failure; Mitral Disease
• Interventions: Device: Transcatheter Mitral Valve Replacement

• Registration Number: NCT03661398
• Lead Sponsor: Caisson Interventional LLC

Brief Summary

The purpose of this study is to assess the safety and performance of Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of severe, symptomatic mitral regurgitation (MR).

Detailed Description

The treatment guidelines for valvular heart disease indicate that surgical correction of primary mitral valve regurgitation (MR) is a Class I recommendation. Recent evidence indicates that valve replacement is at least as effective as repair in both primary and secondary MR patients. However, many patients are not referred for surgery as they are considered to be too high of a risk to undergo on-pump, open-heart procedures. Percutaneous aortic valve replacement has made treatment of stenosed aortic valves available to high-risk surgical patients who would have otherwise been medically managed. Percutaneous mitral valve (MV) replacement offers similar advantages. The feasibility of percutaneous MV replacement has been demonstrated in early feasibility studies. To meet this medical need, Caisson Interventional has developed a percutaneous delivery system for a bioprosthetic mitral valve. As with patients with aortic valve (AV) deficiencies, this device can be used to provide needed therapy to patients who might not otherwise receive treatment beyond medical therapy. This study will provide information on the safety and performance of this system.

Study Timeline

• Study Start: 2017-07-20
• Study First Submitted: 2018-09-05
• Study First Submitted QC: 2018-09-05
• Study First Posted: 2018-09-07
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-27
• Last Update Posted: 2020-01-28
• Primary Completion: 2020-08
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• Has severe mitral regurgitation
• New York Heart Association (NYHA) Class II, III, IVa or heart failure
• High risk for cardiovascular surgery

Exclusion Criteria

• Excessive calcification or thickening of mitral valve annulus
• Severe mitral stenosis, fused commissures, valvular vegetation or mass
• Left ventricular end diastolic dimension > 7cm
• Left ventricular outflow tract obstruction
• Severe right ventricular dysfunction
• Stroke within 90 days; transient ischemic attack or myocardial infarction within 30 days of the index procedure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Transcatheter Mitral Valve Replacement	Transcatheter Mitral Valve Replacement	Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System

Primary Outcome Measures

Name	Time	Method
Number of patients without Major Adverse Events (MAEs)	30 days	Freedom from major adverse events including death, stroke, myocardial infarction and surgical reintervention through 30 days

Secondary Outcome Measures

Name	Time	Method
Number of patients with successful delivery and implantation of the prosthetic valve (technical success)	Intra-operative	Successful delivery and retrieval of the transcatheter mitral valve delivery system; deployment and correct positioning (via intraoperative imaging) in the appropriate anatomic location of prosthetic valve with no requirement for additional surgery
Number of living, stroke-free patients with prosthetic valve in place (device success)	30 days	Patient is alive, stroke-free, original intended device in place (echo), no mitral valve surgical re-intervention required

Trial Locations

Locations (1)

Pennsylvania State University; 🇺🇸 Hershey, Pennsylvania, United States